Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
FIS heads into November earnings with the Street losing conviction, a stock down a fifth in a month, and analysts queuing up to lower their sights.
The most striking fact about FIS right now is the scale of the price move. The stock closed at $33.42 on Tuesday, down 20% from a month ago, yet only fractionally changed on the week. That combination, a sharp month-long slide followed by a brief pause, is where the narrative sits. The next scheduled earnings print is November 6, and the last time FIS reported, the stock fell 4.3% on the day and 4.5% over the following week. History does not flatter the setup.
Analyst sentiment has been moving in one direction. Deutsche Bank trimmed its target to $40 from $45 as recently as September 29, maintaining a Hold. Baird followed a few days earlier, cutting to $45 from $48, also at Neutral. Piper Sandler initiated at Neutral with a $42 target in mid-September. The direction of travel across the Street is clear: targets are coming down, and the dominant rating is neutral to cautious. The mean target across all analysts is $49.41, which implies significant theoretical upside from $33.42, but given the recent trajectory of cuts, that headline figure is arguably stale before the ink is dry. TD Cowen remains the most visible bull, holding a Buy with a $53 target, but even that was trimmed from $58 in August. Wells Fargo went a step further in late August, downgrading outright to Equal-Weight and cutting to $46 from $58. The bears point to margin pressure, banking sector consolidation, and acquisition integration drag. The bulls cite H2 visibility in the Banking segment and a management case for roughly 150 basis points of EBITDA margin expansion in Q4. Both sides are watching the same November print.
Valuation has compressed alongside the share price. The price-to-earnings multiple has fallen by roughly 1.3 turns over the past 30 days to 5.1x. Price-to-book is below 1.0 at 0.98x, down more than 0.25x over the same period. EV/EBITDA is running near 5.0x. These are not expensive multiples for a large payments processor, but factor scores do not offer much reassurance: EPS momentum ranks in the 39th percentile on a 30-day basis and falls further to the 27th on a 90-day view. Forward earnings growth ranks in just the 11th percentile. The quality and value flags are arguably supportive at these levels, but momentum is absent.
Short positioning does not add much to the bear case. Short interest sits at just 3.1% of free float, down about 4% on the week, and has been broadly declining since a brief spike to around 25 million shares in mid-September. Borrow conditions are among the loosest in the market: availability is running at roughly 7,073%, meaning shares to borrow vastly outnumber shares already borrowed, and the cost to borrow is just 0.36%, near the lowest of the past 30 days. The ORTEX short score is 33.7, in the lower-middle of its range and stable over the past two weeks. None of this points to a short-driven story. The pressure on FIS is coming from somewhere else.
Options traders are mildly more constructive than they were. The put/call ratio has dropped to 0.67, below its 20-day average of 0.73, after running as high as 0.97 in late September. That late-September defensive spike coincided with the sharpest phase of the monthly price decline. The pullback in the PCR since then suggests the most acute hedging demand has eased, though the ratio remains well within normal bounds rather than signalling outright bullish positioning.
On the ownership side, Capital Research and Management added more than 20 million shares in the period to September 30, a notable accumulation at a time when others were trimming. Fuller and Thaler added over 8 million shares through August, and Charles Schwab Investment Management added roughly 4 million. Dodge and Cox remains the largest disclosed holder at around 9.5% of shares. All 13D/G filings are passive; no activist is on the register. The disclosure caveat applies: stakes are as-last-disclosed and a holder below 5% may not file again.
The question heading into November 6 is whether the margin trajectory management has guided for, roughly 150 basis points of Q4 EBITDA expansion, holds up against what has been a weakening consensus view across most of the sell side that has moved on the name this quarter.
See the live data behind this article on ORTEX.
Open FIS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
